000129236 001__ 129236
000129236 005__ 20240228143413.0
000129236 0247_ $$2doi$$a10.1002/ajh.24533
000129236 0247_ $$2pmid$$apmid:27508939
000129236 0247_ $$2ISSN$$a0361-8609
000129236 0247_ $$2ISSN$$a1096-8652
000129236 0247_ $$2altmetric$$aaltmetric:10474116
000129236 037__ $$aDKFZ-2017-05241
000129236 041__ $$aeng
000129236 082__ $$a610
000129236 1001_ $$aMerz, Maximilian$$b0
000129236 245__ $$aBaseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
000129236 260__ $$aNew York, NY$$bWiley-Liss$$c2016
000129236 3367_ $$2DRIVER$$aarticle
000129236 3367_ $$2DataCite$$aOutput Types/Journal article
000129236 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525683878_14692
000129236 3367_ $$2BibTeX$$aARTICLE
000129236 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000129236 3367_ $$00$$2EndNote$$aJournal Article
000129236 520__ $$aDeletion 17p13, del(17p), is associated with poor outcome in myeloma but some patients show long-term survival. With the current study we intended to identify factors impacting outcome of such high risk patients. We analyzed 110 newly diagnosed, symptomatic patients with del(17p) detected by fluorescence in situ hybridization (FISH) in CD138-purified myeloma cells to identify prognostic factors for survival. Age >65 years, ISS III, and elevated LDH negatively impacted survival. Patients with subclonal (10-60% of plasma cells) del(17p) had longer progression-free survival (PFS) than patients with del(17p) in >60% of plasma cells (26 vs. 19 months, P = 0.03). Additional gain of 1q21 was associated with shorter PFS (17 vs. 25 months, P = 0.01). Hyperdiploidy did not ameliorate impact of del(17p), but gain 19q13 predicted longer PFS (30 vs. 18 months, P = 0.01) and overall survival (50 vs. 29 months, P = 0.01). Multivariate analysis in transplant eligible patients (≤65 years) revealed better survival for patients treated with upfront autologous transplantation (hazard ratio, [95% confidence interval]: 0.15 [0.04, 0.58], P = 0.006). Application of maintenance therapy was associated with better survival in transplant-eligible patients (0.30 [0.09, 0.99], P = 0.05). We demonstrate heterogeneous outcome of patients with del(17p) according to baseline characteristics and treatment. 19q13 should be included in routine FISH panel, since gains were associated with better survival. Am. J. Hematol. 91:E473-E477, 2016. © 2016 Wiley Periodicals, Inc.
000129236 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000129236 588__ $$aDataset connected to CrossRef, PubMed,
000129236 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000129236 7001_ $$aSeckinger, Anja$$b2
000129236 7001_ $$aHose, Dirk$$b3
000129236 7001_ $$00000-0002-6226-1252$$aMai, Elias K$$b4
000129236 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b5$$udkfz
000129236 7001_ $$0P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aGoldschmidt, Hartmut$$b6$$udkfz
000129236 7001_ $$aJauch, Anna$$b7
000129236 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b8$$eLast author$$udkfz
000129236 773__ $$0PERI:(DE-600)1492749-4$$a10.1002/ajh.24533$$gVol. 91, no. 11, p. E473 - E477$$n11$$pE473 - E477$$tAmerican journal of hematology$$v91$$x0361-8609$$y2016
000129236 909CO $$ooai:inrepo02.dkfz.de:129236$$pVDB
000129236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000129236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000129236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000129236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000129236 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000129236 9141_ $$y2016
000129236 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000129236 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J HEMATOL : 2015
000129236 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000129236 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000129236 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000129236 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000129236 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000129236 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000129236 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000129236 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000129236 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000129236 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000129236 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000129236 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x1
000129236 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x2
000129236 9201_ $$0I:(DE-He78)V964-20160331$$kV964$$lNCT-KliHD$$x3
000129236 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x4
000129236 980__ $$ajournal
000129236 980__ $$aVDB
000129236 980__ $$aI:(DE-He78)C060-20160331
000129236 980__ $$aI:(DE-He78)G170-20160331
000129236 980__ $$aI:(DE-He78)G330-20160331
000129236 980__ $$aI:(DE-He78)V964-20160331
000129236 980__ $$aI:(DE-He78)E010-20160331
000129236 980__ $$aUNRESTRICTED